-

QIAGEN to Launch QuantiFERON SARS-CoV-2 For Research Into Causes, Spread and Control of COVID-19 Through T-cell Response

T-cell response has the potential to give a clearer picture of immunity and course of illness 

• T-cell response to SARS-CoV-2 may decline less rapidly than antibodies

• Potentially vital tool for research into immune response and vaccination efficacy

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect T-cell responses of the human immune system to the pathogen that causes COVID-19, which could help researchers find out more about immunity levels and disease progression.

Studies suggest that T-cell response to SARS-CoV-2 declines much more slowly than antibody response, which presents several benefits to researchers who want to push beyond the existing detection of active infections to screen for potential courses of the illness and long-term immune responses to it. QIAGEN’s QuantiFERON SARS-CoV-2 Research Use Only (RUO) solution could be a valuable tool in this research.

There is also growing evidence that T-cell response gives a reliable indication of how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those who have recovered remain months – possibly even years – after having been infected.

QuantiFERON SARS-CoV-2 RUO is a flexible, modular system designed to meet a wide range of research demands. It is based on QIAGEN’s easy-to-use QuantiFERON technology, pioneered in the QuantiFERON-TB Gold Plus test for latent tuberculosis and recognized worldwide for its ability to detect interferon gamma that T-cells release upon contact with certain pathogens.

QuantiFERON SARS-CoV-2 RUO is a crucial addition to QIAGEN’s growing COVID-19 portfolio that already provides sample-preparation technology, infection testing with polymerase chain reaction (PCR) technology, antibody and antigen tests, enzymes and automation solutions.

Please find the full press release here

Contacts

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

QIAGEN N.V.

NYSE:QGEN
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Summary
QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response
Release Versions
$Cashtags

Contacts

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Social Media Profiles
More News From QIAGEN N.V.

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston. The first public introduction of QIAsymphony Connect builds on more than 3,000 cumulative placements at the end of 2024 of the first-generation v...

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets. QIAGEN reaffirmed its FY 2025 outlook for net sales growth of about 4-5% CER (about 5-6% CER core sales excluding divestments) and raised its adjusted diluted EPS target to about $2.38 CER (previously about $2.35 CER). QIAGEN also expects an adjusted opera...

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

VENLO, Netherlands & SEATTLE--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The acquisition will significantly expand QIAGEN’s Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions and bi...
Back to Newsroom